/C O R R E C T I O N -- Gallant/
In the news release, Gallant Debuts GallantU: A Comprehensive CE Platform Preparing Veterinary Professionals for the Regenerative Medicine Era, issued 09-Sep-2025 by Gallant over PR Newswire, we are advised by the company that the website in paragraph five has been updated. The complete, corrected release follows:
Gallant Debuts GallantU: A Comprehensive CE Platform Preparing Veterinary Professionals for the Regenerative Medicine EraLive and on-demand courses cover the latest in stem cell biology and ready-to-use therapies, led by board-certified veterinarians, clinicians, and researchers at the forefront of regenerative medicine
SAN DIEGO, Sept. 9, 2025 /PRNewswire/ -- Gallant, an animal health biotechnology company pioneering ready-to-use stem cell therapies for pets, announced the launch of its proprietary online continuing education (CE) platform, GallantU. Built with general practitioners in mind, GallantU represents a significant step forward in veterinary education – offering a comprehensive training program to help veterinary professionals lead confidently in the regenerative medicine era.
GallantU courses cover the science, clinical use, and future potential of allogeneic, ready-to-use stem cell therapy—a new class of drugs actively explored for their ability to modulate immune responses, reduce inflammation, and help restore health at the source. By addressing the root cause rather than just providing temporary relief, this technology marks a shift from symptom management to actual disease modification.
Through a mix of live sessions and on-demand content, GallantU participants will receive a solid foundation in the fundamentals of stem cell therapy, exploring the immunomodulatory and disease-modifying potential for a variety of conditions, including oral inflammatory diseases, osteoarthritis, dermatological diseases, and neurological conditions. Led by board-certified veterinarians, clinicians, and researchers at the forefront of regenerative medicine, GallantU offers a rigorous, practice-oriented launchpad into this new category of veterinary care.
"Seeing the impact of stem cell therapy has been extraordinary—watching pets who might otherwise have faced euthanasia or lifelong medical management truly improve," said Dr. Rebecca Windsor, Director of Veterinary Affairs at Gallant. "Now that these therapies are becoming ready-to-use, standardized, and available on demand, they are poised to become part of mainstream veterinary care. We developed GallantU as a go-to resource for stem cell education, helping veterinary professionals understand how they work and when they may be appropriate for their patients. As Gallant advances through the FDA drug approval process to bring the first ready-to-use stem cell therapy into everyday practice, our goal is to ensure practitioners feel confident and prepared for the regenerative medicine era."
GallantU is open to veterinarians, veterinary technicians and nurses, and other professionals looking to expand their knowledge in regenerative medicine. To sign up and start learning at no cost, visit https://www.gallant.com/gallantU.
About Gallant
Gallant is an animal health biotechnology company creating a new category of veterinary medicine with a pipeline of ready-to-use stem cell therapies targeting the root causes of diseases in pets. Led by pioneers in veterinary regenerative medicine with deep expertise in development, manufacturing, and commercialization, Gallant is making regenerative medicine accessible—moving beyond symptom management to restoring health at the source. Learn more at https://www.gallant.com/.
Contact:
Galyna Danylenko
+1 (443) 254-7567
400893@email4pr.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/gallant-debuts-gallantu-a-comprehensive-ce-platform-preparing-veterinary-professionals-for-the-regenerative-medicine-era-302550363.html
SOURCE Gallant